What is PathoQuest?
PathoQuest specializes in biosafety assays, leveraging next-generation sequencing (NGS) for the quality testing of biologics. The company's core offerings include GMP biotesting for biopharmaceuticals, focusing on critical services such as adventitious virus testing, cell line characterization, and genetic analysis. PathoQuest provides an ethical and efficient alternative to traditional testing methods, aiming to enhance the safety and compliance of biotherapies. Their commitment to rapid, reliable quality control is vital for both global and emerging biopharma companies navigating the complex development of innovative therapies.
How much funding has PathoQuest raised?
PathoQuest has raised a total of $13.8M across 2 funding rounds:
Unspecified
$5M
Other Financing Round
$8.8M
Unspecified (2013): $5M with participation from Idinvest Partners, Kurma Partners, and Aurinvest
Other Financing Round (2019): $8.8M led by investiere, Idinvest Partners, French Public Program Investissement D'Avenir, Charles River Labs, Norgine, and Kurma Partners
Key Investors in PathoQuest
investiere
investiere is a European startup investment platform focused on qualified and institutional investors, specializing in European high-tech startups after rigorous due diligence.
Idinvest Partners
Idinvest Partners is a mid-market private equity company that finances and supports entrepreneurs at various stages of their business development, founded in 1997.
Norgine
Norgine is a leading European specialist pharmaceutical company, established in 1906, dedicated to bringing transformative medicines to patients.
What's next for PathoQuest?
With a substantial enterprise-level funding context, PathoQuest is poised for significant scaling and innovation. The recent strategic investment will likely fuel advancements in their NGS platform, potentially expanding service offerings and market reach. Future developments may include deeper integration into the biopharmaceutical supply chain, further solidifying their role in ensuring the safety and efficacy of novel therapeutics. Continued investment in R&D and strategic partnerships will be crucial for PathoQuest to maintain its competitive edge and achieve its vision of transforming biotherapy development.
See full PathoQuest company page
